1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER
Lung Disorder
Explore 25 assets in Lung Disorder →Floatz Rating
CCC55/100
Confidence
Indicative
Sponsor
Children's Oncology Group
Modality
protein_peptide
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00309907CT.gov Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lung Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| 1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER (this asset) | Children's Oncology Group | P2 | CCC · 55 |
| Carboplatin | Jiangmen Central Hospital | P3 | B |
| Theophylline | NCIC Clinical Trials Group | P3 | B |
| Lumacaftor | Vertex Pharmaceuticals Incorporated | P3 | B |
| Pembrolizumab | Sarah Goldberg | P3 | B |
| Ivacaftor | University of British Columbia | P3 | B |
| Pralsetinib, Trans- | Hoffmann-La Roche | P3 | B |
| Cis-Diamminedichloroplatinum Ii | Jiangmen Central Hospital | P3 | B |
| Buspirone | University of Rochester | P2/3 | CCC |
+41 more in the Lung Disorder cohort
Other indications for 1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Psoriasis | — | P4 | BBB · 72 |
| Skin Carcinoma | — | P4 | B · 62 |
| Sciatica | — | P2/3 | B · 61 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. 1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER in Lung Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/1-235-tumor-necrosis-factor-receptor-human-fusion-protein-with-236-467-immunoglobulin-g1-human-gamma1-chain-fc-fragment-dimer-lung-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →